2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

4:30PM-6:00PM: Abstract Number: 1050

Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy II: Small Molecular Targeted Therapies

4:30PM-6:00PM: Abstract Number: 1089

Responsiveness of Physical Activity Measures Following Exercise Intervention in Individulas after Total Knee Arthroplasty

ACR/ARHP Combined Abstract Session: Rehabilitation

4:30PM-6:00PM: Abstract Number: 1027

Rheumatoid Arthritis Disease Activity Assessment Frequencies in Clinical Practices Do Not Support Treat-to-Target Care

Quality Measures and Quality of Care

4:30PM-6:00PM: Abstract Number: 1076

Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics I

4:30PM-6:00PM: Abstract Number: 1051

Serum Calprotectin As Biomarker of Carotid Atherosclerosis in Patients with Primary Sjögren’s Syndrome

Sjögren's Syndrome I: Basic Insights

4:30PM-6:00PM: Abstract Number: 1067

Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

4:30PM-6:00PM: Abstract Number: 1071

Single-Cell RNA Sequencing of Human Podocytes, Endothelial Cells, and Tubular Cells Identifies Markers and Gene Profiles Differentiating Class IV and Class V Renal Disease in Lupus Nephritis

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics

4:30PM-6:00PM: Abstract Number: 1035

Synovium-Derived microRNAs Inhibit Bone Formation in Rheumatoid Arthritis

Rheumatoid Arthritis - Animal Models I

4:30PM-6:00PM: Abstract Number: 1066

Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations

Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

4:30PM-6:00PM: Abstract Number: 1013

The Fellow As Clinical Teacher Curriculum: Improving Rheumatology Fellows’ Teaching Skills during Inpatient Consultation

Education

4:30PM-6:00PM: Abstract Number: 1079

The Potential Effect on Recruitment of Restricting Skin Scores Eligibility Criteria in Early Diffuse Scleroderma Trials

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics I

4:30PM-6:00PM: Abstract Number: 1039

The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response

Rheumatoid Arthritis - Clinical Aspects I - Treatment Advances and Strategies

4:30PM-6:00PM: Abstract Number: 1075

The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics I

4:30PM-6:00PM: Abstract Number: 1060

The View of Healthy Persons on the Impact of Spondyloarthritis on Functioning and Health: Results of a Best-Worst Scaling Based on the ASAS Health Index

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

4:30PM-6:00PM: Abstract Number: 1038

Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation

Rheumatoid Arthritis - Animal Models I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].